PEDIATRIC ONCOLOGY GROUP PARTICIPATION

儿科肿瘤小组参与

• 批准号: 3557156
• 负责人: CHING-HON PUI
• 金额: $ 20.22万
• 依托单位: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1982
• 资助国家: 美国
• 起止时间: 1982-01-01 至 1995-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3557156
• 关键词: child (0-11); clinical trials; cooperative study; human subject; human therapy evaluation; pediatric neoplasm /cancer

We propose continued participation in the Pediatric Oncology Group (POG). Our goals are as follows: (1) to improve cure rates for children with cancer through participation in Phase I, II, and III clinical trials designed to test new agents or concepts; and (2) to participate in laboratory-based research aimed at clarifying the basis of drug resistance and pathogenetic mechanisms of childhood cancers. We are committed to Group participation because we believe: (1) that collaborative efforts are both desirable and necessary for study of childhood cancers, since all are relatively rare; and, (2) that well-designed randomized clinical trials provide the most definitive test of efficacy and general applicability of new therapies and that pooled intellectual resources are advantageous as well. our contribution to the Group can be categorized as follows: (1) contribution of selected patients (those with rare tumors or less common stages of other cancers, n is approximately 60-70/year) to Group studies; (2) administrative and scientific leadership (Group vice-chairman; disease committee chairmen including pathology, psychology, brain tumor, and lymphoid; and protocol coordination); (3) provision of multiple reference laboratories [flow cytometry analyses of acute lymphoblastic leukemia (ALL), Ewing sarcoma, neuroblastoma, osteosarcoma and rhabdomyosarcoma, B and pre-B cell typing, cell bank for ALL and the solid tumors noted above]; (4) regular presentation of results of in-house research to the Group. Since our center has an unusually large number of patients and staff (both clinical and basic), the latter contribution assumes unusual importance. We have an extensive in-house developmental therapeutics program which is independent of, but complementary to, the Group's clinical research programs. We also have extensive programs in basic research. The aim of these programs, to determine the pathogenesis of pediatric neoplasia, is expected to positively influence the Group's central goal -- curing children with cancer.

我们建议继续参与儿科肿瘤学组 (POG)。 我们的目标是：（1）提高儿童的治愈率 通过参与 I、II 和 III 期临床试验来治疗癌症 旨在测试新药物或概念； (2) 参与 旨在阐明耐药性基础的实验室研究 和儿童癌症的发病机制。 我们致力于 团体参与是因为我们相信：(1) 协作努力是 对于儿童癌症的研究来说既可取又必要，因为所有这些都是 相对罕见； (2) 精心设计的随机临床试验 提供最明确的功效和普遍适用性测试 新疗法和汇集智力资源的优势在于 出色地。我们对集团的贡献可分为以下几类： (1) 选定患者（患有罕见肿瘤或不太常见的肿瘤的患者）的贡献 其他癌症的分期，n 约为 60-70/年）进行小组研究； （2）行政和科学领导（组副主席；疾病 委员会主席包括病理学、心理学、脑肿瘤和 淋巴；和协议协调）； (3) 提供多重参考 实验室[急性淋巴细胞白血病的流式细胞术分析 (ALL)，尤文肉瘤，神经母细胞瘤，骨肉瘤和横纹肌肉瘤，B 以及前 B 细胞分型、ALL 和上述实体瘤的细胞库]； (4) 定期向集团汇报内部研究成果。 由于我们中心的患者和工作人员数量异常多（均为 临床和基础），后者的贡献显得异常重要。 我们有一个广泛的内部发育治疗计划 独立于集团的临床研究，但与之互补 程序。 我们还有广泛的基础研究项目。 的目的 这些程序旨在确定儿科肿瘤的发病机制 预计将对集团的中心目标——治愈产生积极影响 患有癌症的儿童。